A New Concept: Pre‐HCC Disease
Yao Yang, Yuemin Feng, Xinya Zhao, Le Wang, Xiaoyu Xie, Jie Li, Mindie H. Nguyen, Qiang Zhu – 2 August 2018
Yao Yang, Yuemin Feng, Xinya Zhao, Le Wang, Xiaoyu Xie, Jie Li, Mindie H. Nguyen, Qiang Zhu – 2 August 2018
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
Ghassan Mubarak, Richard Ferstenberg – 2 August 2018
Hannele Yki‐Järvinen, Panu K. Luukkonen – 2 August 2018
Amit G. Singal, Jasmin A. Tiro, Caitlin C. Murphy, Jorge A. Marrero, Katharine McCallister, Hannah Fullington, Caroline Mejias, Akbar K. Waljee, Wendy Pechero Bishop, Noel O. Santini, Ethan A. Halm – 2 August 2018 – Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis; however, effectiveness is limited by underuse. We compared the effectiveness of mailed outreach and patient navigation strategies to increase HCC surveillance in a racially diverse cohort of patients with cirrhosis.
Yang Shen, Mark J. Czaja – 2 August 2018
Laura C. Burlage, Sarah Bos, Jelle Adelmeijer, Takumi Sakai, Robert J. Porte, Ton Lisman – 1 August 2018 – Recombinant human soluble thrombomodulin (ART‐123) is an anticoagulant and anti‐inflammatory agent clinically used for treatment of disseminated intravascular coagulation. Preclinical studies have shown that ART‐123 reduces hepatic ischemia/reperfusion. Although ART‐123 may therefore have clinical benefit in orthotopic liver transplantation, the substantial alterations in the hemostatic system may complicate its use in this setting.
Dante Lamberti, Giulia Cristinziano, Manuela Porru, Carlo Leonetti, Jan B. Egan, Chang‐Xin Shi, Simonetta Buglioni, Carla A. Amoreo, Loriana Castellani, Mitesh J. Borad, Stefano Alemà, Sergio Anastasi, Oreste Segatto – 1 August 2018 – About 15% of intrahepatic cholangiocarcinomas (ICCs) express constitutively active fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs) generated by chromosomal translocations.
Neil Mehta, Jennifer L. Dodge, Ryutaro Hirose, John P. Roberts, Francis Y. Yao – 1 August 2018 – Given the increasing incidence of hepatocellular carcinoma (HCC) and regional variation in liver transplantation (LT) rates for HCC, we investigated temporal and geographic disparities in LT and wait‐list dropout. LT candidates receiving Model for End‐Stage Liver Disease (MELD) exception from 2005 to 2014 were identified from the United Network for Organ Sharing database (n = 14,320). Temporal differences were compared across 2 eras (2005‐2009 and 2010‐2014).